Using genetic markers in clinical practice David Thomas Advisor: Merck Clinical trial: Gilead and Merck.
Frequencies of Resistance-Associated Amino Acid Variants Following Combination Treatment with Boceprevir (BOC) Plus PEGINTRON (PegInterferon Alfa-2b) and.
Non invasive fibrosis markers and/or liver biopsy Pierre Bedossa Department of Pathology, Hôpital Beaujon, Paris-Denis Diderot University FRANCE.
5/14/2015 1 Interim Results from HCV SPRINT-1 Phase 2 Study of Boceprevir Plus Peginterferon alfa-2b/Ribavirin in Treatment-Naïve Subjects with Genotype-1.
Peginterferon Alfa-2a plus Ribavirin vs Peginterferon Alfa-2b plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV- Infected Patients J Berenguer.
SPRINT-1 Methods
Funding sources :
Jenny HEATHCOTE. Chronic Hepatitis C “The Non Responder”! Jenny Heathcote MD University of Toronto.
Hepatitis web study H EPATITIS W EB S TUDY H EPATITIS C O NLINE Boceprevir (Victrelis) Prepared by: David Spach, MD & H. Nina Kim, MD Last Updated: March.
